4503 On Other Exchanges
4503 is not on other exchanges.

astellas pharma inc (4503) Snapshot

Previous Close
Day High
Day Low
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ASTELLAS PHARMA INC (4503)

Related News

No related news articles were found.

astellas pharma inc (4503) Related Businessweek News

View More BusinessWeek News

astellas pharma inc (4503) Details

Astellas Pharma Inc., a pharmaceutical company, manufactures, markets, and imports and exports pharmaceutical products worldwide. The company offers Prograf and Advagraf/Graceptor/ASTAGRAF XL/Prograf XL, an immunosuppressant used to suppress organ transplant rejection; Vesicare, a treatment for overactive bladder; Harnal/Omnic, a blocking agent to treat the functional symptoms of benign prostatic hyperplasia; and Funguard/MYCAMIN, a candin-type antifungal agent. It also provides Geninax, an oral new-type quinolone antibacterial agent; Celecox, an anti-inflammatory agent; Lipitor, a treatment for hypercholesterolemia; Micardis/Micombi/Micamlo, a treatment for hypertension; Gaster, a treatment for peptic ulcer and gastritis; Betanis/Myrbetriq/BETMIGA, a beta-3 adrenergic agonist indicated for the treatment of overactive bladder; Eligard, a luteinizing hormone-releasing hormone agonist for the treatment of prostate cancer; XTANDI for the treatment of prostate cancer; and VESOMNI, a release tablet for the treatment of moderate to severe storage symptoms and voiding symptoms associated with benign prostatic hyperplasia in men who are not adequately responding to treatment with monotherapy. In addition, the company offers Symbicort for the treatment for adult bronchial asthma and chronic obstructive pulmonary disease; Bonoteo for the treatment for osteoporosis; Suglat for the treatment of type 2 diabetes; and Repatha for the treatment of hypercholesterolemia. Further, the company provides Lexiscan, a pharmacologic stress agent; Tarceva, a treatment for non-small cell lung cancer; CRESEMBA, a azole antifungal; and Dificlir, a novel treatment for CDI. Additionally, it is developing enzalutamide, gilteritinib, and degarelix for oncology indications. The company has a collaborative research partnership with Astellas Pharma Inc. Astellas Pharma Inc. was founded in 1923 and is headquartered in Tokyo, Japan.

17,202 Employees
Last Reported Date: 06/19/17
Founded in 1923

astellas pharma inc (4503) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

astellas pharma inc
Cardurion Pharmaceuticals Licenses Clinical Stage Heart Failure Candidate from Astellas Pharma Inc

Cardurion Pharmaceuticals announced it has entered an exclusive licensing agreement with Astellas Pharma Inc. to develop and commercialize CRD-733, a PDE-9 inhibitor with the potential to improve cardiac function in heart failure patients. Under the terms of the agreement, Astellas has granted Cardurion Pharmaceuticals an exclusive, worldwide, royalty-bearing license to research, develop, manufacture and commercialize CRD-733 for the diagnosis, prevention and treatment of cardiovascular-related indications in humans.

Astellas Announces Executive Changes

Astellas announced the appointment of Tatjana Dragovic, J.D. to head, Ethics & Compliance. She will oversee Astellas' Ethics & Compliance efforts globally, with responsibility for all Astellas Ethics & Compliance team members. She succeeds Catherine Wertjes, J.D. who is retiring after 18 years with Astellas and 33 years in the pharmaceutical industry. Dragovic joined Astellas in 2007 as senior corporate attorney and held positions of increasing responsibility from assistant general counsel to associate general counsel, litigation. She was appointed to vice president of Ethics & Compliance for Astellas' Americas region in June 2014 and added responsibility for the group's operations globally in 2016. In this role, she not only oversaw compliance strategies and programs for Astellas in the U.S., Canada and Latin America, but also had responsibility for risk assessment, investigations, monitoring, policy & processes as well as compliance training and communications globally.

Actinium Pharmaceuticals, Inc. Announces Collaborative Research Partnership with Astellas Pharma Inc. Leveraging Actinium's AWE Platform Technology

Actinium Pharmaceuticals, Inc. announced that it has entered into a research and option agreement with Astellas Pharma Inc. (Astellas) to develop Actinium-225 Radio-Conjugates (ARCs) using its Actinium Warhead Enabling (AWE) Platform Technology. Under this collaboration, Actinium will utilize its AWE Platform to conjugate and label selected Astellas targeting agents with the powerful actinium-225 ((225) Ac) payload. Actinium will also be responsible for conducting preclinical validation studies on the novel ARCs generated. Actinium will receive a seven-digit payment which includes upfront fee and research funding from Astellas.


The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

4503 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 4503.
View Industry Companies

Industry Analysis


Industry Average

Valuation 4503 Industry Range
Price/Earnings 18.4x
Price/Sales 2.5x
Price/Book 2.4x
Price/Cash Flow 15.5x
TEV/Sales 2.3x

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact ASTELLAS PHARMA INC, please visit www.astellas.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.